These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19106301)

  • 1. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.
    Di Nicolantonio F; Arena S; Gallicchio M; Zecchin D; Martini M; Flonta SE; Stella GM; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A
    Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20864-9. PubMed ID: 19106301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
    Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recessive oncogenes.
    Bookstein R; Allred DC
    Cancer; 1993 Feb; 71(3 Suppl):1179-86. PubMed ID: 8428341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.
    Wang H; Han H; Mousses S; Von Hoff DD
    Semin Oncol; 2006 Aug; 33(4):513-20. PubMed ID: 16890805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward increased sensitivity and specificity in the treatment of neoplastic diseases.
    Slavkin HC
    J Am Dent Assoc; 1998 Apr; 129(4):473-8. PubMed ID: 9573699
    [No Abstract]   [Full Text] [Related]  

  • 7. Systems for identifying new drugs are often faulty.
    Gura T
    Science; 1997 Nov; 278(5340):1041-2. PubMed ID: 9381203
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicine. Building better mouse models for studying cancer.
    Marx J
    Science; 2003 Mar; 299(5615):1972-5. PubMed ID: 12663895
    [No Abstract]   [Full Text] [Related]  

  • 9. Rational design of cancer gene panels with OncoPaD.
    Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
    Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance.
    Fatemian T; Chowdhury EH
    Curr Cancer Drug Targets; 2014; 14(7):599-609. PubMed ID: 25308718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
    Di Cintio A; Di Gennaro E; Budillon A
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of tumor suppressor genes.
    Morris LG; Chan TA
    Cancer; 2015 May; 121(9):1357-68. PubMed ID: 25557041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target selection issues in drug discovery and development.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
    Wierstra I
    Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Big genes are big mutagen targets: a connection to cancerous, spherical cells?
    Parry ML; Ramsamooj M; Blanck G
    Cancer Lett; 2015 Jan; 356(2 Pt B):479-82. PubMed ID: 25451318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer target discovery using SAGE.
    Porter D; Polyak K
    Expert Opin Ther Targets; 2003 Dec; 7(6):759-69. PubMed ID: 14640911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ordered mutations on dynamics in signaling networks.
    Mazaya M; Trinh HC; Kwon YK
    BMC Med Genomics; 2020 Feb; 13(Suppl 4):13. PubMed ID: 32075651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene in drug-resistant variants of a human sarcoma.
    Chen KG; Lacayo NJ; Durán GE; Wang Y; Bangs CD; Rea S; Kovacs M; Cherry AM; Brown JM; Sikic BI
    Genes Chromosomes Cancer; 2002 Aug; 34(4):372-83. PubMed ID: 12112526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
    Mashima T
    Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.